Allosteric modulation of the M1 muscarinic acetylcholine receptor: improving cognition and a potential treatment for schizophrenia and Alzheimer's disease-Reference-Cited by-同舟云学术

Allosteric modulation of the M1 muscarinic acetylcholine receptor: improving cognition and a potential treatment for schizophrenia and Alzheimer's disease

Published:2013-12 Issue:23-24 Volume:18 Page:1185-1199
ISSN:1359-6446
Container-title:Drug Discovery Today
language:en
Short-container-title:Drug Discovery Today

Author:

Melancon Bruce J.,Tarr James C.,Panarese Joseph D.,Wood Michael R.,Lindsley Craig W.

Publisher

Elsevier BV

Subject

Drug Discovery,Pharmacology

Reference94 articles.

1. Schizophrenia;Mueser;Lancet,2004

2. When doors of perception close: bottom-up models of disrupted cognition in schizophrenia;Javitt;Annu. Rev. Clin. Psychol.,2009

3. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review;Newcomer;CNS Drugs,2005

4. What are the functional consequences of neurocognitive deficits in schizophrenia?;Green;Am. J. Psychiatry,1996

5. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial;Keefe;Arch. Gen. Psychiatry,2007

Cited by 110 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discovery of VU6007496: Challenges in the Development of an M₁ Positive Allosteric Modulator Backup Candidate;ACS Chemical Neuroscience;2024-08-28

2. What Remains to Be Discovered in Schizophrenia Therapeutics: Contributions by Advancing the Molecular Mechanisms of Drugs for Psychosis and Schizophrenia;Biomolecules;2024-07-25

3. Design and Synthesis of Clinical Candidate PF-06852231 (CVL-231): A Brain Penetrant, Selective, Positive Allosteric Modulator of the M₄ Muscarinic Acetylcholine Receptor;Journal of Medicinal Chemistry;2024-06-18

4. G protein-coupled receptors (GPCRs): advances in structures, mechanisms and drug discovery;Signal Transduction and Targeted Therapy;2024-04-10

5. Concentration–QTc Relationship from a Single Ascending Dose Study of ANAVEX3‐71, a Novel Sigma‐1 Receptor and Allosteric M1 Muscarinic Receptor Agonist in Development for the Treatment of Frontotemporal Dementia, Schizophrenia, and Alzheimer's Disease;Clinical Pharmacology in Drug Development;2023-07-28